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Abstract
Background: The EphB4 receptor tyrosine kinase has been reported as increased in tumours
originating from several different tissues and its expression in a prostate cancer xenograft model
has been reported.
Methods: RT-PCR, western blotting and immunohistochemical techniques were used to examine
EphB4 expression and protein levels in human prostate cancer cell lines LNCaP, DU145 and PC3.
Immunohistochemistry was also used to examine localisation of EphB4 in tissue samples from 15
patients with prostate carcinomas.
Results: All three prostate cancer cell lines expressed the EphB4 gene and protein. EphB4
immunoreactivity in vivo was significantly greater in human prostate cancers as compared with
matched normal prostate epithelium and there appeared to be a trend towards increased
expression with higher grade disease.
Conclusion: EphB4 is expressed in prostate cancer cell lines with increased expression in human
prostate cancers when compared with matched normal tissue. EphB4 may therefore be a useful
anti-prostate cancer target.
Background
Prostate cancer is the most frequent cause of cancer death
in men in Australia. Although many genetic changes have
been detected in human prostate cancer, the role of most
of these in initiation and progression of the disease is
unclear. Receptor tyrosine kinases (RTKs) couple ligand
binding to downstream signalling cascades and gene tran-
scription and are key regulators of normal cellular proc-
esses such as growth, differentiation, migration and
apoptosis. RTKs are also critically involved in the develop-
ment and progression of human cancers and are therefore
useful targets for anti-cancer therapies [1,2]. At least 50
RTKs in 20 different families have been identified and the
largest family of these contains the Eph receptors [3]. This
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into two classes, designated A and B, based on sequence
homology, structure and ligand binding affinity [4,5]. The
ligands for the Eph receptors are called ephrins and are
anchored on the plasma membrane through either a glyc-
osyl phosphatidylinositol (GPI) link (ephrin-A) or a
transmembrane domain (ephrin-B) [6].
Ligand binding induces receptor autophosphorylation of
intracellular tyrosine, threonine and serine residues and
allows interactions with a variety of different proteins that
regulate cell functions such as contact inhibition,
cytoskeletal organisation and cell motility [7,8]. Several
studies have described intricate signalling networks often
important to cell proliferation, migration, survival and
differentiation [reviewed in [9]] that centre around Eph
receptors and their ligands.
Members of both classes of Eph receptor have been found
to have increased gene expression and/or protein levels in
tumours from many different human tissues [10-20]. In
particular EphB4, located at chromosome 7q22.1, and ini-
tially isolated from a human hepatocellular carcinoma
cell line Hep3Ba [10] has been reported by us and others
to be highly expressed in many tumour tissues including
colon [11,12], breast [13,14], endometrium [15,16], lung
[17] and head and neck [18,19]. Robinson et al (1996)
used degenerate RT-PCR oligonucleotide primers specific
to two conserved motifs in the tyrosine kinase domains of
40 different kinases to amplify those kinases that are
expressed in a prostate cancer xenograft model [20].
EphB4 was identified as one of the RTKs expressed in the
xenograft tissue. More recently, Xia et al (2005) report that
EphB4 is commonly expressed in prostate tumour tissues
and cell lines and knockdown of EphB4 protein using
siRNA and antisense approaches inhibited cell growth/
viability, migration and invasion both in vitro and in vivo
[21]. Concurrently with Xia et al's study, in this pilot study
we also investigated the expression patterns of the EphB4
gene and its protein product in prostate cancer cell lines
and tumour tissue samples.
Methods
Cell culture
Human prostate cancer cell lines LNCaP, DU145 and PC3
were cultured in HEPES-buffered RPMI 1640 medium
(Invitrogen, Carlsbad, CA), pH 7.4. The medium was sup-
plemented with 100 U/ml penicillin, 100 µg/ml strepto-
mycin, 160 µg/ml L-glutamine and 10% heat-inactivated
foetal bovine serum (JRH Biosciences, Lenexa, KS) in 75
cm2 vented tissue culture flasks at 37°C in a 5% CO2 envi-
ronment. Cells were collected at >90% confluency by
trypsin digestion and centrifugation for 5 min at 1000
rpm, resuspended in phosphate buffered saline (PBS) and
counted using a haemocytometer.
RNA extraction from cell lines
RNA was isolated from cell lines using Tri Reagent (Invit-
rogen). Growth medium was aspirated from the flask of
growing cells (>90% confluent) and the cells washed with
phosphate-buffered saline (PBS) before being directly
lysed using 1 ml of Tri Reagent. After a five min incuba-
tion with gentle rocking, the cell lysate was removed to a
2 ml eppendorf tube. The RNA fraction was extracted
using the manufacturer's recommendations.
Protein extraction from cell lines
Growth medium was aspirated from the flask of growing
cells (>90% confluent) and the cells washed with phos-
phate-buffered saline (PBS) before being directly lysed
using 1 ml of Cell Lytic M Cell Lysis Reagent (Sigma) sup-
plemented with 5 µl Protease Inhibitor Cocktail (Sigma).
Protein lysate was removed to a 1.5 ml microfuge tube
and the solution mixed for 30 min at 4°C on a rotary
mixer. Insoluble protein was pelleted by centrifugation at
4°C for 30 min and the supernatant containing the solu-
ble proteins was stored at -80°C until required for West-
ern analysis. Protein concentrations were determined
using the DC Protein Assay Kit from Biorad (Sydney,
NSW, Australia) following the manufacturer's protocol
and using bovine serum albumin diluted from 0.1 mg/ml
to 10.0 mg/ml to determine the standard curve.
Real-time RT-PCR to determine relative expression of 
EphB4
Total RNA (2 µg) was reverse transcribed at 37°C using 3
µl pD(N)6 primers (Invitrogen), 200 µM each deoxyribo-
nucleoside triphosphate (dNTP) (Pharmacia, Uppsala,
Sweden) and 200 U Superscript III reverse transcriptase
(Invitrogen) in a reaction volume of 30 µl. Primers spe-
cific to either EphB4 or the housekeeping genes Porpho-
bilinogen deaminase (PBGD) and Hypoxanthine
phosphoribosyl-transferase 1 (HPRT 1) were used in a
PCR reaction carried out in a BioRad iCycler MyiQ Real
Time thermocycler or a Corbett Rotorgene 3000 (Table I).
The following conditions for the PCR reaction were used:
1.5 mM MgCl2, 200 µM each dNTP, 50 ng of each primer,
and 0.5 units of HotStarTaq DNA polymerase in 1 × PCR
buffer (Qiagen, Melbourne, Australia). Cycling condi-
tions included an initial denaturation at 94°C for 15 min,
followed by 45 cycles of 94°C for 30 sec, 67°C or 68°C
for 30 sec, and 72°C for 30 sec, with a final extension of
72°C for 7 min.
Western analysis
Proteins (50 µg) from samples extracted from prostate
tumour cell lines were separated on duplicate 8% Tris-
Glycine iGels (Gradipore, Sydney, Australia). The protein
separated on one of the gels was visualised by coomassie
staining and the protein on the duplicate gel was electro-
phoretically transferred to MFS nitrocellulose membranePage 2 of 11
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blocked by incubation for 1 h at room temperature using
a Western blocking buffer containing 1% casein in maleic
acid buffer (Roche) diluted using TBS with 0.1% Tween-
20 (TBS-T). EphB4 antigens were detected using a 1:1000
dilution of a mouse monoclonal antibody raised to
human EphB4 (Zymed, CA) in blocking buffer. After a 1
h incubation at room temperature, the primary antibody
was detected using a HRP-labelled anti-mouse secondary
antibody (Roche) and the ECL Western Blotting System
from Amersham Biosciences (Sydney, Australia) follow-
ing the manufacturer's recommendation. Blots were
exposed to Hyperfilm™ECL™ (Amersham Biosciences) for
between 5 and 30 sec. The chemiluminescence was
removed from the blot by incubation in a stripping solu-
tion containing 100 mM β-mercaptoethanol, 2% SDS and
62.5 mM Tris-HCl pH 6.7 for 20 min at 50°C with gentle
agitation. The filter was then washed with TBS-Tween 20
before blocking and re-probing with a mouse anti-α-actin
monoclonal antibody (Chemicon, Temecula, CA) then it
was stripped again and probed with a rabbit anti-calnexin
antibody (Sigma) for loading comparison.
Immunofluorescence of cells grown on slides
Cell were grown to >50% confluence in the wells of 8 well
chambered slides. Before staining, the medium was aspi-
rated and the cells washed gently with PBS. Cells were
then fixed in 4% paraformaldehyde and washed well
before non-specific binding sites were blocked with 3%
serum in PBS for 20 min at room temperature. Cells were
then incubated overnight at 4°C with a 1:200 dilution of
the EphB4-specific rabbit polyclonal antibody H-200
(Santa Cruz Biotechnology, Santa Cruz, CA). After rinsing
with PBS, the sections were incubated with an Alexa Fluor
488 goat anti-rabbit IgG (H+L) (Molecular Probes).
Immunofluorescence was visualised using a TE2000E
microscope with a C1 confocal scanning head (Nikon,
Tokyo, Japan).
Tissue immunohistochemistry
Four consecutive 8 µm sections of formalin-fixed paraffin-
embedded tissue from 15 different patients with prostate
cancer were a gift from Dr Michael Brown, Medical Oncol-
ogy, Royal Adelaide Hospital, Adelaide, Australia. A fifth
slide, stained to visualize the histological features of the
tissue, was used to identify the foci of tumour tissue
within the adjacent normal prostate tissue by a trained
pathologist. The paraffin was removed by incubation in
Histoclear (National Diagnostics, Atlanta, Georgia) and
the section re-hydrated in ethanol before antigen retrieval
by boiling in 10 mM citric acid pH 6 for 10 min. Sections
were cooled, then washed in PBS before removal of
endogenous peroxidase activity by incubation in 0.5%
hydrogen peroxide/methanol for 30 min at room temper-
ature. Non-specific binding sites were blocked with 3%
normal goat serum in PBS for 20 min at room tempera-
ture and the Vector Laboratories (Burlingame, CA) Avi-
din/Biotin blocking kit following the manufacturer's
instructions. The sections were then incubated overnight
at 4°C with a 1:200 dilution of the H-200 EphB4-specific
antibody (Santa Cruz Biotechnology). After rinsing with
PBS, the sections were incubated with biotinylated goat
anti-rabbit IgG (Vector Laboratories) for 30 min at room
temperature followed by washing with PBS. Immunoreac-
tivity was detected with the avidin-biotin system (Vector
Laboratories) using 18.5 mM 3,3'-diaminobenzidine tet-
rahydrochloride (Sigma) as a chromogen for 2 min. The
sections were then counterstained using Harris haematox-
ylin, dehydrated, cleared using SUB-X clearing solution
(Surgipath Medical Industries, Inc. Richmond, IL) and
mounted using Entellan New (Merck, Darmstadt, Ger-
many). Sections were visualised and images recorded
using a Nikon Eclipse E800 microscope with a Spot Cam-
era 2.3.1 (Diagnostic Instruments) and Spot Advanced
Version 3.5 software.
Results
Relative expression of EphB4 in prostate cancer cell lines
The relative expression of EphB4 in three prostate cancer
cell lines was determined using reverse transcription and
real time PCR using two different real-time PCR
machines. Cell lines used included the androgen-depend-
ent line LNCaP derived from a lymph node biopsy (mod-
erately differentiated), the androgen-independent line
Table 1: Primer sequences used to amplify EphB4 and the control housekeeping genes PBGD and HPRT 1 with expected size of the 
corresponding PCR product in base pairs (bp) and the annealing temperature used in the reaction.
Primer Sequence 5'-3' Product Annealing
EphB4 F CCC       CAG GGA AGA AGG AGA GCT G
EphB4 R GCC     CAC GAG CTG GAT GAC TGT G 250 bp 68°C
PBGD F CTT      TCC AAG CGG AGC CAT GTC TGG
PBGD R CAT      GAG GGT TTT CCC GCT TGC AGA 377 bp 68°C
HPRT F GGC    TAT AAA  TTC TTT GCT GAC CTG CTG
HPRT R CAA       AGT CTG CAT TGT TTT GCC AGT GTC 230 bp 67°CPage 3 of 11
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ately differentiated with foci of poorly differentiated cells)
and the androgen-independent line PC3 from a bone
metastasis (poorly differentiated) [22-24]. For each exper-
iment performed amplification reactions were resolved
on agarose gels to confirm products of the predicted size
for each gene were amplified (example shown in Figure
1). In the first instance, the EphB4 gene and the house-
keeping control gene PBGD were amplified in triplicate
from cDNA made using three different RNA extractions
for each cell line (Figure 2A) and a serial dilution of one
of these cDNA preparations (Figure 2B) using a BioRad
iCycler MyiQ. In the second experiment, a second house-
keeping gene, HPRT 1, was amplified in addition to EphB4
and PBGD using a Corbett Rotorgene 3000 (Figure 2C).
For each individual sample, EphB4 expression level was
normalised to the expression of PBGD and HPRT 1 in
these samples (EphB4/PBGD or EphB4/HPRT 1). Compar-
ison of the combined data for each cell line showed that
there was no statistical difference in the level of EphB4
expression in the three prostate cancer cell lines (Figure
2). In a third experiment, RNA was extracted from 6 repli-
cates of cells grown to either full confluence or 50–80%
confluence and EphB4 expression again normalised to
both PBGD and HPRT 1. There was no statistically signif-
icant difference in the level of expression of EphB4 in the
non-confluent and confluent cells for any of the three cell
lines (data not shown).
In these experiments the ratios of EphB4/PBGD and
EphB4/HPRT 1 were all close to 1 indicating that there
RT-PCR analysis of EphB4 expression in prostate cancer cell linesFigure 1
RT-PCR analysis of EphB4 expression in prostate can-
cer cell lines. RT-PCR analysis of EphB4 and PBGD expres-
sion in duplicate RNA samples from the three prostate 
cancer cell lines LNCaP, DU145 and PC3. Sizes of the ampli-
fied products are shown on the right (bp). An RNA sample 
to which no reverse transcriptase was added and a PCR rea-
gent only (containing no template) amplification were also 
performed as negative controls for each stage of the RT-
PCR.
R PM 1 2 1 2 1 2
EphB4 250 bp
PBGD 377 bp
L D P
Normalisation of EphB4 expression to housekeeping genes PBGD nd HPRT1Figure 2
Normalisation of EphB4 expression to housekeeping 
genes PBGD and HPRT1. EphB4 expression normalised to 
PBGD in prostate cancer cell lines LNCaP, DU145 and PC3. 
(A) Triplicate amplifications of EphB4 and PBGD in three sam-
ples for each cell line were analysed to determine the relative 
levels of EphB4 expression using the BioRad iCycler. All 
EphB4/PBGD ratios were close to 1 indicating that there are 
comparable amounts of both templates in each RNA sam-
ples. (B) Dilutions of a single RNA sample for each cell line 
were also amplified in triplicate with both gene primer sets 
to confirm that the ratio was consistent regardless of starting 
template concentration. (C) Triplicate amplifications of 
EphB4, PBGD and HPRT1 in three samples for each cell line 
using the Corbett Rotorgene confirmed the previous result 
for EphB4/PBGD and showed a similar result when EphB4 
expression was normalised to a second housekeeping gene.
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templates in each cell line RNA sample. There was no sta-
tistical difference between the ratios obtained using serial
dilutions of a single cDNA sample for each cell line show-
ing that the amplification is consistent regardless of the
starting amount of template. These results support the use
of both PBGD and HPRT 1 as normalisation controls for
the EphB4 message.
Western analysis of EphB4 protein in prostate cancer cell 
lines
Protein was isolated from the three prostate cancer cell
lines for western analysis to determine whether the level
of gene expression correlated with the amount of protein
present. Duplicate samples were run on two separate gels,
one of these was immunoblotted and the other stained
with coomassie blue to confirm protein integrity and con-
sistency in the amount of protein loaded. The predicted
size of the mature EphB4 protein is 120 kDa and a band
of this approximate size was clearly visible in each sample
after immunoblotting with an EphB4-specific antibody
(Figure 3A). The non-transformed breast cell line
MCF10A engineered to over-express EphB4 under control
of the constitutive CMV promoter was used as a positive
control (labelled +ve in Figure 3). In the prostate cell lines
a second band of a slightly smaller size is also clearly visi-
Western analysis of EphB4 in prostate cancer cell linesFigure 3
Western analysis of EphB4 in prostate cancer cell lines. Western analysis of 20 µg EphB4 protein in prostate cancer 
cell lines LNCaP (L), DU145 (D) and PC3 (P). (A) The immunoblot was incubated sequentially with antibodies specific to 
EphB4, α-actin and calnexin and exposed to autoradiographic film for the indicated times. MCF10A engineered to express 
EphB4 (5 µg protein lysate) was used as a positive control. The arrow indicates the expected size of each protein – 120 kDa 
for EphB4, 43.2 kDa for α-actin and 90 kDa for calnexin. The size of the marker proteins is shown on the left in kDa. (B) 
Coomassie stained duplicate gel for loading comparison.
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BMC Cancer 2005, 5:119 http://www.biomedcentral.com/1471-2407/5/119ble and this may represent an alternatively modified
(phosphorylated/glycosylated) or spliced form of EphB4.
The coomassie staining of the duplicate gel shows that
similar amounts of protein from each cell line was loaded
and suggests that the PC3 cell line produces more EphB4
protein than LNCaP than DU145 (Figure 3B). To confirm
efficient transfer the blot was also incubated sequentially
with an antibody recognizing α-actin. Although a 10 sec
exposure time suggested there were similar levels of pro-
tein present, a shorter exposure showed differences in the
relative amount of actin in each protein lysate. Therefore
a second control antibody recognising the ER chaperone
calnexin was also used. There was little difference in the
relative amounts of calnexin in each sample.
Immunological analysis of expression of EphB4 in prostate 
cancer cell lines
The expression and localisation of EphB4 in the three cell
lines grown on slides was determined using immunofluo-
rescence with an EphB4-specific polyclonal antibody. In
LNCaP and DU145 cells EphB4 appeared to be present on
both the cell surface and in the cytoplasm but in PC3 cells
the EphB4 appeared to be mainly cytoplasmic (Figure 4).
This cytoplasmic localisation of EphB4 in tumour cells
contrasts with its known localisation within sites of cell-
cell contact between non-transformed epithelial cells and
may suggest that active EphB4 signalling has caused endo-
cytosis of the receptor-ligand complex in these cells. Sim-
ilar results have been reported by Wu et al (2004) who
also used the EphB4 antibody sc-5536 from Santa Cruz
Biotechnology in their study of EphB4 expression in
Immunofluorescent staining of EphB4 in prostate cancer cell linesFigure 4
Immunofluorescent staining of EphB4 in prostate cancer cell lines. Immunofluorescent staining of EphB4 in prostate 
cancer cell lines showing diffuse staining on the surface and in the cytoplasm of LNCaP and DU145 and in the cytoplasm only of 
PC3. There was no reactivity to the primary antibody (EphB4 1° only) or secondary antibody (2° only) alone and little back-
ground fluorescence (No staining).
LNCaP
DU145
PC3
EphB4 + 20 EphB4 10 only 20 only No stainingPage 6 of 11
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BMC Cancer 2005, 5:119 http://www.biomedcentral.com/1471-2407/5/119breast cancer cell lines and tissue samples [14]. All four
breast cancer cell lines examined showed strong immu-
nostaining in the cytoplasm.
Immunohistochemical analysis of expression of EphB4 in 
primary prostate tumours
To localize the expression of EphB4 in normal prostate
and tumour tissue, we performed immunohistochemistry
using an EphB4-specific antibody on 15 prostate tumour
samples collected by transurethral resection. These patient
samples were chosen because they contained foci of pros-
tate cancer or benign prostatic hyperplasia within the nor-
mal tissue. The results for 8 representative patient sample
sets are presented in Figure 5. The epithelial cells lining
the ducts in the normal tissue can be clearly distinguished
by the rows of regular nuclei stained blue with Harris Hae-
matoxylin. There was either no or only very weak diffuse
staining of the normal epithelial cells, stroma and
endothelial cells of blood vessels indicating little immu-
noreactivity to the EphB4 antibody. There was no staining
with an isotype matched IgG antibody or the secondary
antibody alone in either normal or tumour tissues (results
not shown).
Foci of prostate cancer within these samples showed
brown staining indicating immunoreactivity to the EphB4
antibody and therefore the presence of the EphB4 protein.
A single patient sample had a low level of staining associ-
ated with foci of basal cell hyperplasia. In this case EphB4
may be involved in a proliferative role [25]. There also
appeared to be an increase in the amount of staining
associated with an increase in Gleason score. There was lit-
tle staining in the 5 different patient samples that con-
tained foci of well-differentiated adenocarcinoma (2
examples are shown in Figure 5), and increased staining in
the three patients with foci of moderately differentiated
and the three patients with poorly differentiated adeno-
carcinomas. Because prostate cancer is multifocal, each
sample was examined to determine if it contained foci of
different grades and whether immunoreactivity differed in
intensity within these. As these samples were collected
during transurethral resection to debulk enlarged pros-
tates, and were later found to contain foci of disease, only
a few samples contained foci of different grades. One
patient in particular had large regions classified clinically
as prostatic intraepithelial neoplasia (PIN) and staining
within these foci was surprisingly of equal intensity to the
regions of poorly differentiated adenocarcinoma (Figure
6).
Discussion
In recent years, experiments using monoclonal antibodies
with limited normal-tissue reactivity have indicated that
these are good candidates for development as therapeutic
agents against cancer. EphB4 is a receptor protein tyrosine
kinase (RTK) that is dramatically up-regulated on many
epithelial cancers, displays limited expression on normal
adult tissue and would therefore appear to be a potential
target for monoclonal therapies. EphB4 was identified by
Robinson et al (1996) as one of several RTKs that were
expressed in a xenograft model of prostate cancer [20] and
until recently this was the only report of any link between
EphB4 expression and prostate cancer.
During the review of this article, Xia et al (2005) presented
results showing that EphB4 is increased in 66% (41/62) of
prostate tumours tested with low intensity expression in
only 15% (3/20) normal prostate samples [21]. Our west-
ern analysis of PC3, LNCaP and DU145 confirmed Xia et
al's results [21], with higher amounts of protein present in
PC3 lysates that LNCaP and DU145. In the case of DU145
this can perhaps be explained by regulation of EphB4 gene
expression as real-time PCR using normalisation to two
different house-keeping genes demonstrated that there
was approximately 20% less EphB4 transcript expressed in
the DU145 cell line than in LNCaP and PC3 (P < 0.05).
However, as there was no significant difference in the
activity of the gene in LNCaP and PC3, it is possible that
EphB4 may also be regulated post-transcriptionally. The
presence of a second band detected by western analysis
with the EphB4-specific antibody may also indicate that
EphB4 is regulated post-translationally and this needs to
be explored in more detail.
Although Xia et al's study of cell lines also indicated an
association between the level of EphB4 expression and
aggressive growth, they did not report a direct correlation
between increased EphB4 expression with higher grade of
the tumour tissue samples. We examined a panel of 15
prostate cancer clinical specimens collected by transure-
thral resection. The prostate tumour samples we exam-
ined contained both normal prostate and tumour foci and
this enabled a comparison of EphB4 immunoreactivity in
normal prostate and tumour cells simultaneously from
the same patient and the determination of whether the
level of EphB4 also correlates with histological grade and/
or stage of prostate carcinoma. Using immunohistochem-
ical techniques, we showed that EphB4 is produced in
increased amounts in human prostate cancer tissue com-
pared with adjacent normal tissue and that this
immunoreactivity was associated with the tumour epithe-
lial cells themselves. There also appeared to be trend
towards an increasing level of EphB4 protein in the
tumours from the well-differentiated to the moderately
and poorly differentiated cancers.
A positive correlation between histological grade, stage of
carcinoma and level of EphB4 protein has also been
reported in breast and endometrial carcinoma [13-16].
EphB4 has been reported to be elevated in breast primaryPage 7 of 11
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BMC Cancer 2005, 5:119 http://www.biomedcentral.com/1471-2407/5/119Immunohistochemical staining of EphB4 in prostate cancer samplesFigure 5
Immunohistochemical staining of EphB4 in prostate cancer samples. The expression of EphB4 in human prostate 
carcinomas was detected using immunohistochemical staining of formalin fixed, paraffin-embedded tissue samples. Images (20× 
magnification) of normal (panel 2) and diseased tissue (panel 4) from eight different patient samples are shown with a Haema-
toxylin/eosin stained consecutive section (panels 1 and 3). The Gleason score for each disease focus is shown in the top left-
hand corner of the image of each tumour focus. A single sample that contained a focus of basal cell hyperplasia, two samples 
with well-differentiated adenocarcinoma, two samples of moderately differentiated adenocarcinoma and three samples of 
poorly differentiated adenocarcinoma are shown. The brown stain from the biotinylated secondary antibody indicates the 
EphB4 protein. Nuclei are stained with Harris haematoxylin and appear blue. Staining of normal tissues was either absent or 
weak and diffuse. Increased staining of the tumour tissue appeared to correlate with increased Gleason score. There was no 
cross-reactivity with the secondary antibody alone (result not shown).Page 8 of 11
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malignancy [13] and recently Wu et al (2004) reported
that EphB4 protein expression in 94 tumour samples was
positively associated with increased clinical stage and his-
tological grade [14]. Sakano et al, (1996) suggested that
the balance of EphB4 and its preferred ligand ephrin-B2 is
disrupted when mammary epithelial cells become trans-
formed [25] and loss of ephrin-B2 expression has been
associated with an increase in EphB4 expression [26].
However contrary to this Berclaz et al (2002) report a
highly significant correlation between EphB4 positivity
and low histological grade [27]. One of the patients exam-
ined here also showed a comparable level of EphB4 stain-
ing in foci of PIN and poorly differentiated
Immunohistochemical staining of EphB4 in several foci of a single prostate cancer sampleFigure 6
Immunohistochemical staining of EphB4 in several foci of a single prostate cancer sample. The expression of 
EphB4 a different foci in a single patient sample was compared by immunohistochemistry. Images from 10× magnification (A) 
and a region from this (as indicated by the box) at 20× magnification (B) are shown for 2 regions of normal prostate duct (1 
and 2) and 8 regions with disease (3–10) from this single sample. A comparable level of EphB4 staining was seen in regions of 
high grade PIN (eg. focus 8 indicated PIN) and regions of poorly differentiated adenocarcinoma (eg. focus 7 indicated PDA). 
Regions of well-differentiated (eg focus 3) and moderately differentiated (eg focus 10) also show comparable staining.Page 9 of 11
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noma in this case, this might suggest that increased
expression of EphB4 was an early event in the develop-
ment of this patient's disease. Furthermore, a single focus
of basal cell hyperplasia in a second patient did show a
low level of EphB4 immunoreactivity and this may indi-
cate a role for EphB4 in proliferation of these cells [25].
The results presented here suggest that elevated levels of
EphB4 are relevant to prostate cancer but despite substan-
tial evidence in the literature that EphB4 has an important
role in progression of many epithelial tumours, the mech-
anism by which these receptors contribute to tumorigen-
esis is still being resolved. In only a very few cases have
Eph receptors been demonstrated to have transforming
potential [28-30]. In particular, a study reported by Zelin-
ski et al (2002) showed that EphA2 expression transforms
MCF10A cells as judged by conversion to a fibroblastic
morphology, growth in soft agar and the ability to engraft
and metastasise in a nude mouse model [29].
Although similar experiments over-expressing EphB4 in
non-transformed cell lines have yet to be reported, a study
by Munarini et al (2000) using transgenic mice expressing
EphB4 and neuT suggested that EphB4 over-expression by
itself is not tumorigenic but provides convincing evidence
that it favours an invasive/metastatic phenotype [31].
Although mammary tumours were not observed in the
EphB4 transgenic animals, in double transgenic animals
expressing both EphB4 and neuT, tumour appearance was
significantly accelerated relative to neuT-only animals,
and in addition metastases were observed in the lung. It
was not clear if this was an effect of EphB4 on metastasis
or a result of accelerated tumour growth but these results
clearly implicate over-expression of EphB4 in tumour
growth and/or establishment of the invasive phenotype in
the adult mammary tumours. While the single transgenic
EphB4 animals did not develop tumours during this
experiment it is possible that these studies were not taken
out far enough to conclude that EphB4 over-expression is
insufficient to induce transformation with a long latency.
Xia et al's (2005) recent experiments targeting EphB4
using siRNA to knockdown EphB4 expression in vitro have
shown that EphB4 is involved in growth/viability, migra-
tion and invasion of prostate cancer cell lines and sup-
ports Munarini et al's study [21]. Furthermore, EphB4
antisense oligonucleotides were given intraperitoneally to
nude mice bearing PC3 xenografts in the posterior pros-
tate (n = 6), tumours were fewer and smaller, with
increased apoptosis and reduced microvascular density
than sense- or diluent-treated control animals. The reduc-
tion in microvascular density is particularly interesting
given that in other epithelial tumours, EphB4-positive
cells are often found in regions that are rich in capillaries
[13] and it has been suggested that EphB4 over-expression
in tumours may promote tumour growth by facilitating
angiogenesis.
A direct role for EphB4 in tumour angiogenesis has been
suggested by experiments showing that A375 melanomas
form smaller tumours in the presence of soluble EphB4
[32] possibly because the soluble EphB4 interferes with
binding of endogenous EphB4 on tumour cells to ephrin-
B2 on endothelial cells. A role in angiogenesis would be
consistent with the normal role for EphB4 in vascular
development and remodelling demonstrated in mouse
and Xenopus [33,34]. Noren et al (2004) contradict this
finding in a study that found that increased expression of
a signaling-defective form of EphB4 in breast cancer cells
(dominant negative) was still able to make tumour
xenografts grow more rapidly [35]. This may be because
the EphB4 ectodomain exerted a chemoattractive effect on
endothelial cells through ephrin-B2 expressed on these
cells and promoted endothelial cell proliferation and sur-
vival resulting in more tumour vasculature. However,
Noren et al applied a high concentration of soluble
ephrin-B2 Fc which is promiscuous and signals other Eph
receptors (particularly EphB2) but the phosphorylation of
other EphRs was not determined in this study.
Conclusion
Further investigation is needed to determine the roles of
EphB4 in prostate cancer development and progression.
The trend of increasing EphB4 reactivity toward higher
grade disease seen in this pilot study might suggest that it
is more important in the later stages of the tumour devel-
opment such as metastasis and further investigation of
EphB4 in the development of prostate cancer is war-
ranted. Therapies that target EphB4 may prove to be suc-
cessful in preventing the metastatic spread of the disease.
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